===== Content Start =====
What is the Cost of PGT-A Screening in China
The cost of PGT-A (Preimplantation Genetic Testing for Aneuploidy) screening at public tertiary hospitals in China is approximately 5,000–12,000 RMB per single embryo, which includes the two core steps of embryo biopsy and genetic testing. The biopsy step costs about 2,000–4,000 RMB per embryo, and the testing step costs about 3,000–8,000 RMB per embryo. If a conventional egg retrieval cycle produces 3–5 blastocysts for testing, the total screening cost ranges from 15,000 to 50,000 RMB.
Cost Breakdown
PGT-A screening is not a single item but a service chain composed of multiple technical steps. The following table shows the fee range and description for each step:
| Fee Item | Fee Range (RMB/Embryo) | Description |
|---|---|---|
| Embryo Biopsy Fee | 2,000–4,000 | Sampling 3–5 cells from the trophectoderm of a day 5–6 blastocyst |
| Genetic Testing Fee | 3,000–8,000 | Whole chromosome screening using NGS or aCGH platform |
| Genetic Counseling Fee | 500–2,000/session | Pre-test genetic counseling + post-test result interpretation (usually one session each) |
| Embryo Freezing Fee | 1,000–3,000/year | Cryopreservation of embryos during screening and while awaiting results |
| Cycle Management Fee | 2,000–5,000/cycle | Charged separately by some hospitals, covering lab coordination and quality control |
Note: The above are common pricing ranges from major reproductive centers in China for 2024–2025. Actual costs are subject to the hospital's official price list.
Key Factors Influencing Costs
Differences in Screening Technology Platforms
Currently, two main technology platforms are used clinically in China, with differences in cost and pricing:
- NGS (Next-Generation Sequencing): Testing fee per embryo is approximately 5,000–8,000 RMB. It can detect aneuploidy for all 23 chromosome pairs and copy number variations (CNVs) >5Mb, offering higher resolution.
- aCGH (Array Comparative Genomic Hybridization): Testing fee per embryo is approximately 3,000–5,000 RMB. It can detect aneuploidy for all 23 chromosome pairs and CNVs >10Mb, with mature technology and relatively controllable costs.
Some hospitals standardize the pricing for both technologies, mainly depending on the laboratory's equipment investment and platform choice. NGS has a slight advantage in identifying mosaicism and small fragment abnormalities, making it more commonly used for older patients or those with repeated implantation failure.
Hospital Level and Nature
| Hospital Type | Cost Range per Embryo Screening | Characteristics |
|---|---|---|
| Public Tertiary Reproductive Center | 5,000–9,000 RMB | Standardized pricing, some items may be covered by insurance (subject to local policies), longer waiting times |
| Private Fertility Hospital | 8,000–12,000 RMB | Streamlined service process, often includes one-on-one coordination and report interpretation |
| Sino-foreign Joint Venture / High-end Clinic | 10,000–15,000 RMB | Utilizes overseas technology platforms and quality control systems, higher laboratory standards |
Pricing differences among different types of hospitals mainly stem from operational costs, equipment investment, and service packages, and do not directly reflect the effectiveness of the technology.
Number of Embryos and Tiered Pricing
Most reproductive centers adopt a tiered pricing strategy with decreasing costs based on the number of embryos:
- 1–2 embryos: Charged at the full individual embryo price, no discount
- 3–5 embryos: Total price discounted by 10%–20%
- 6 or more embryos: Total price discounted by 20%–30%
For example, at a public hospital: the single embryo testing fee is 6,000 RMB, a package for 3 embryos is 15,000 RMB (approximately 16% discount), and a package for 5 embryos is 22,000 RMB (approximately 26% discount). Specific discount rates should be confirmed with the hospital before treatment.
Whether Genetic Counseling is Included
Genetic counseling before and after PGT-A screening is a standard procedure. Some hospitals include the counseling fee in the testing package, while others charge it separately. Genetic counseling usually requires 2 sessions (one before and one after testing), each costing 500–2,000 RMB, totaling approximately 1,000–4,000 RMB. If complex genetic interpretation is involved (e.g., mosaicism, variants of uncertain significance), the counseling cost may be higher.
Easily Overlooked Cost Details
Biopsy Fee and Testing Fee Calculated Separately
Some hospitals list the biopsy fee and testing fee as two separate charge items. During consultation, patients may easily focus only on the "testing fee" and overlook the biopsy part. The biopsy fee accounts for about 30%–40% of the total screening cost and is a significant cost component.
Embryo Freezing and Storage Fees
After blastocyst biopsy, the embryos need to be cryopreserved. Waiting for test results usually takes 2–4 weeks, and then they must be stored until the transfer cycle. Freezing fees are generally charged annually. Some hospitals offer the first year free, with subsequent years costing 1,000–3,000 RMB per year. If transfer is not performed promptly after screening, this cost can be easily underestimated.
Repeat Screening Costs
Approximately 3%–8% of blastocysts may require re-biopsy and re-testing due to DNA amplification failure, inconclusive results, or ambiguous mosaicism. The cost for repeat testing is usually 50%–70% of the original price, and the biopsy fee must be paid again. This possibility is typically explained in the informed consent form, but patients often do not pay sufficient attention to it.
Billing Method After Cycle Cancellation
If the number of blastocysts formed after egg retrieval is lower than expected (e.g., only one), some hospitals still charge the original package price, while others re-calculate based on the actual number of embryos tested. It is advisable to clarify the fee handling rules in case of cycle cancellation or insufficient embryo count before signing the informed consent form.
How Doctors View the Cost of PGT-A
From a clinical reproductive medicine perspective, PGT-A screening is not suitable for all IVF patients. Cost is one factor in the decision-making process but should not be the primary determining condition.
Groups with Clear Benefit:
- Women aged ≥38 years
- Repeated implantation failure (≥3 failed transfers with good quality embryos)
- Recurrent miscarriage (≥2 spontaneous miscarriages)
- Known carriers of chromosomal abnormalities (including balanced translocations, Robertsonian translocations, etc.)
Groups with Unclear Benefit:
- Age < 35 years with normal ovarian function (AMH ≥1.5 ng/mL, antral follicle count ≥8)
- First IVF attempt with no history of adverse pregnancy outcomes
- No clear genetic indication
For groups with unclear benefit, PGT-A screening may become an unnecessary financial burden, and embryo biopsy carries a risk of damage of about 1%–2%. When recommending screening, clinicians will assess factors including the patient's age, ovarian reserve, previous pregnancy history, and number of embryos.
Cost-Benefit Analysis by Age Group
Women Under 35
The embryo aneuploidy rate is approximately 20%–30%. If 5 blastocysts are formed, the screening cost is about 20,000–30,000 RMB, and it is expected to identify 1–2 abnormal embryos. From a cost-benefit perspective, the improvement in pregnancy rate from screening is limited, and it is not the preferred strategy.
Women Aged 38–40
The embryo aneuploidy rate rises to 40%–50%. Screening 5 blastocysts can identify about 2–3 abnormal embryos, potentially increasing the success rate per single transfer by 15%–25%. The cost is about 25,000–40,000 RMB, and the clinical benefit is relatively clear.
Women Over 42
The embryo aneuploidy rate can reach 70%–80%. Screening 5 blastocysts may yield only 1–2 chromosomally normal embryos. The cost is about 30,000–50,000 RMB, but it can effectively avoid the greater financial and psychological costs associated with repeated failed transfers.
Practitioner Observation: Cost Transparency Issues
In clinical consultations, patients often have two common misconceptions regarding PGT-A costs:
- Misconception 1: Believing PGT-A is a "one-time fee covering everything." In reality, fees are charged per step of the process, including stimulation, egg retrieval, blastocyst culture, biopsy, testing, freezing, and transfer. Screening itself is just one part of the process.
- Misconception 2: Believing that a normal embryo is guaranteed after screening. Approximately 30%–60% of blastocysts (depending on age) are found to be aneuploid, meaning there may be no normal embryos available for transfer after paying for screening. This fee is non-refundable.
It is recommended to request a detailed fee schedule from the hospital before deciding to proceed with PGT-A, and to clarify which items are fixed charges and which are billed based on actual occurrence.
Frequently Asked Questions
Q: Is the cost of PGT-A screening covered by medical insurance?
Currently, domestic medical insurance coverage for assisted reproductive technology is limited. Some provinces and cities (e.g., Beijing) have included some assisted reproduction items in insurance, but PGT-A, as a genetic testing item, is still self-funded in most regions. Specific reimbursement policies should be confirmed with the local medical insurance department and the treating hospital.
Q: Are the screening fee and transfer fee separate?
Yes. The screening fee only covers the process from embryo biopsy to issuing the genetic report. Subsequent costs for frozen embryo thawing, transfer surgery, and luteal phase support are calculated separately, typically around 10,000–20,000 RMB.
Q: If no normal embryos are found after screening, is the fee refunded?
No. The biopsy and testing services have already been performed, and the fee must be paid regardless of the result. This is a key point that needs to be communicated during clinical genetic counseling.
Q: Are screening results from different hospitals mutually recognized?
No. Different hospitals use different testing platforms, technical standards, and quality control systems, so screening results cannot be used across hospitals. If you change hospitals, re-screening is required.
Risk Reminder
PGT-A screening is an invasive embryonic test. Although the technology is mature, there is a 1%–2% risk of embryo damage. Additionally, results may have a possibility of false positives (approximately 2%–5%) and false negatives (approximately 1%–3%), and the interpretation of mosaic embryos remains somewhat controversial. Cost should not be the sole criterion for deciding whether to undergo PGT-A screening. It is recommended to make a comprehensive assessment under the guidance of genetic counseling and clinical doctors, considering your age, ovarian function, number of embryos, and past pregnancy history. Any decision regarding costs should be made with a full understanding of the technical limitations and clinical benefits.
Comments (0)